<DOC>
	<DOC>NCT00889226</DOC>
	<brief_summary>A randomized, open label, dose titration study to evaluate the efficacy and safety of Pitavastatin compared to atorvastatin in Type 2 Diabetes Mellitus with hypercholesterolemia</brief_summary>
	<brief_title>Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia</brief_title>
	<detailed_description>To evaluate the effect of pitavastatin compared to atorvastatin on the change of Lipid profiles, ApoA1, ApoB, adiponectin and baPWV as a marker of atherosclerosis in Type 2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Age: 25yrs~75yrs Fasting TG &lt;400mg/dL, LDLC ≥130mg/dL 3months &gt; Diagnosed Type2 DM, With OAD, HbA1c ≤ 10.0% or First Diagnosed Type2 DM, 6.5%≤HbA1c≤10.0% Type1 DM, Gestational diabetes Patient need to treat with Insulin Patient with operational treatment for severe diabetic complication Uncontrolled Hypothyroidism Unstable angina, MI, transient ischemic attack(TIA), Stroke, PCI, Heart Failure within 3 months (NYHA class4) Severe Hypertension (SBP ≥ 180 or DBP ≥ 110mmHg) Renal disorder (Serum creatinine ≥ 2.0mg/dL) Hepatic disorder (AST or ALT ≥ 2.5 X UNL) Creatinine Kinase &gt; 2.5 X UNL Gravida or lactation phase Administration of Atorvastatin, Rosuvastatin, Pitavastatin</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>pitavastatin</keyword>
	<keyword>PWV</keyword>
	<keyword>ESPRIT</keyword>
	<keyword>Pitavastatin and Atorvastatin</keyword>
	<keyword>Adiponectin</keyword>
	<keyword>fasting insulin</keyword>
	<keyword>hs-CRP</keyword>
	<keyword>baPWV</keyword>
</DOC>